Source comparison
MK-677 Blood Sugar Insulin Glucose — Comparison by Dose and Duration
12.5mg daily × 8 weeks +3 to +7 mg/dL +10 to +18% Minimal. Typically remains <2.5 No measurable change Low-dose protocols show modest glucose elevation without crossing clinical thresholds in metabolically healthy users. Ideal for those monitoring closely 25mg
This comparison does not assign a generated winner or score.
- 12.5mg daily × 8 weeks
- +3 to +7 mg/dL
- +10 to +18%
- Minimal. Typically remains <2.5
- No measurable change
- Low-dose protocols show modest glucose elevation without crossing clinical thresholds in metabolically healthy users. Ideal for those monitoring closely
- 25mg daily × 8 weeks
- +8 to +15 mg/dL
- +20 to +35%
- Moderate. HOMA-IR rises to 2.5–3.2 range
- +0.1 to +0.3%
- Standard research dose produces measurable insulin resistance by week 8. Manageable with dietary carbohydrate restriction and resistance training
- 25mg daily × 16+ weeks
- +12 to +20 mg/dL
- +30 to +50%
- Significant. HOMA-IR often exceeds 3.5
- +0.3 to +0.6%
- Extended use without breaks compounds metabolic stress. HbA1c may cross into prediabetic range (≥5.7%) even in non-diabetic users
- 25mg daily × 6 weeks on / 2 weeks off
- +5 to +10 mg/dL (avg)
- +15 to +25% (avg)
- Reduced. Cyclic use limits HOMA-IR creep
- Minimal to none if cycled <12 weeks total
- Cycling mitigates long-term insulin resistance accumulation. Glucose and insulin revert partially during off-weeks